PRCT Company Profile and Key Details

PRCT has shown mixed momentum, gaining 9.6% over the past week and -0.38% over the past quarter, though year-to-date performance is up 9.6%. Short-term trend indicators are mixed aligned (SMA20 -1.94%, SMA50 0.74%, SMA200 -26.98%). The stock’s 14-day RSI is 48.8 (neutral), while the ATR of 1.75 points to higher daily volatility. The stock remains sitting in the mid-range of its 52-week band, trading -62.46% below its high and over 18.09% above its low. Average 10-day trading volume of 1.13 million shares is below the 3-month average of 1.41 million, indicating normal recent market interest.

PROCEPT BioRobotics Corporation (NASDAQ:PRCT) closed at $32.83 USD, losing -$1.65 (-4.79%) from the previous close of $34.48. The stock is currently mid-range between its 52-week high and low $27.80 and $85.00. With a market capitalization of about $1.83 billion, PROCEPT BioRobotics Corporation is classified as a small-cap and shows market-like volatility (beta ~0.99). Key stats such as the average daily volume over the past year has been around 1.43 million shares, volume is running light vs its 52-week average. Headquartered in San Jose, CA, PROCEPT BioRobotics Corporation operates in the Healthcare sector and the Medical - Devices industry. Led by CEO Larry L. Wood, the company employs approximately 756 people and listed since September 15, 2021. PROCEPT BioRobotics Corporation, a surgical robotics company, develops transformative solutions in urology.

PROCEPT BioRobotics Corporation has 55.64 million shares outstanding. The public float is 53.56 million shares, elevated short interest at 17.19% of float. This equals 8.07 million shares. The short ratio is 5.15 days. Institutional investors hold 102.82% of the float. Insiders own 4.63%. CPMG Inc holds 11.22 million shares, MOLL FREDERIC H has 863.16 thousand shares and VIKING GLOBAL INVESTORS LP has 400.00 thousand shares. Over the past six months, insider transactions show net buying. They sold 0.00 shares across 0 transactions.

Dividend and splits history remains an important factor for investors monitoring long-term returns.

PROCEPT BioRobotics Corporation generated EPS of -$1.54 over the past year. Five-year average earnings growth is -12.56%. Wall Street analysts project EPS growth of 29.42% annually over the next five years. The latest quarter delivered EPS of -$0.38. The next quarter is forecast at -$0.32. Next year's EPS is expected at $13.49. Analyst sentiment is bullish. Analyst rating data shows there are 8 Strong Buy ratings, 5 Buy ratings, 1 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $95.00 to $50.00. The high target offers 189.37% upside. The low target suggests 52.3% downside. The mean target is $60.71. This offers 84.92% upside. PROCEPT BioRobotics Corporation earnings surprise history is frequent misses against expectations. The quarter that ended November 04, 2025, missed forecasts by -7.32%. The prior quarter beat by -14.63%. Over the last six quarters, Apple has recorded several small beats. These include -3.85% in August 01, 2024.

PROCEPT BioRobotics Corporation (NASDAQ:PRCT) shares are flat 9.6% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows PROCEPT BioRobotics Corporation trading at a premium to the broader market with a P/E of -21.63. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $63.55, suggesting 93.57% upside. Our AI forecast model points to short-term weakness (-2.1% over two weeks), a medium-term fall (-16.66% over three months), and a longer-term gain (22.02% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that PROCEPT BioRobotics Corporation stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -2.1%, with price expected at $32.14 by January 23, 2026, within a range of $30.34 to $33.92 3-Month Outlook: Projected fall of -16.66%, reaching $27.36 by April 09, 2026, with a range of $24.61 to $29.61. 1-Year Outlook: Projected gain of 22.02%, with price at $40.06 by December 31, 2026, within a range of $32.28 to $46.24.

PROCEPT BioRobotics Corporation trades at a P/E ratio of -21.63, slightly below the S&P 500 average, with a price-to-sales ratio of 6.12 and a price-to-book ratio of 4.81 trading at moderately above to book value. The P/FCF stands at -23.01, also below market averages.